(Q35630212)

9 August 2017

title

Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation (English)

1 reference

Duchenne muscular dystrophy

9 August 2017

main subject

1 reference

Sunkyung Kim

1

1 reference

9 August 2017

Kimberly A Campbell

2

1 reference

9 August 2017

Deborah J Fox

3

1 reference

9 August 2017

Dennis J Matthews

4

1 reference

9 August 2017

Rodolfo Valdez

5

1 reference

9 August 2017

MD STARnet

6

1 reference

9 August 2017

publication date

20 November 2014

1 reference

Journal of Child Neurology

9 August 2017

published in

1 reference

9 August 2017

volume

30

1 reference

9 August 2017

issue

10

1 reference

9 August 2017

page(s)

1275-1280

1 reference

Corticosteroids in Duchenne muscular dystrophy: major variations in practice

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

The role of corticosteroids in muscular dystrophy: a critical appraisal

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Why we need observational studies to evaluate the effectiveness of health care

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Deflazacort treatment of Duchenne muscular dystrophy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up

25 September 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4439376

25 September 2018

https://api.crossref.org/works/10.1177%2F0883073814558120

Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands

21 January 2018

1 reference

12 December 2020

Steroids in duchenne muscular dystrophy — Deflazacort trial

1 reference

12 December 2020

Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy

1 reference

12 December 2020

Deflazacort in Duchenne dystrophy: study of long-term effect

1 reference

12 December 2020

A comparison of observational studies and randomized, controlled trials

1 reference

12 December 2020

Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation

1 reference

12 December 2020

Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit

1 reference

12 December 2020

Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

1 reference

12 December 2020

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

1 reference

12 December 2020

When are observational studies as credible as randomised trials?

1 reference

12 December 2020

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy

1 reference

12 December 2020

Identifiers

DOI

10.1177/0883073814558120

1 reference

9 August 2017

1 reference

9 August 2017

1 reference